会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 95. 发明授权
    • Longitudinal condition tracking system and method
    • US11145391B1
    • 2021-10-12
    • US16518403
    • 2019-07-22
    • Health Vector LLC
    • Dan M. Mirica
    • G16H10/20G16H50/20H04L9/06G06F16/182G16H10/60
    • A system and method for coordinating cooperative diagnosis construction, decreasing diagnostic error, reducing delays and repetition in performing tasks, and improving application of data gathering devices through structured data tracking of symptoms, diagnoses, conditions and records using encrypted, event-based blockchain ledgers distributed throughout a network of processors. Symptom and diagnosis devices are used to collect participant data. Data is encrypted and used to generate a secure chain of decentralized ledger blocks. The secure chain is stored in a network of secure processing devices. Data access is controlled by a gatekeeper. Structured data blocks are integrated, creating a comprehensive digital record that may be shared without sacrificing control. Pathology collections are generated from integrated data. Interfaces are used to provide reports and directives to allow participants to leverage data and perform tasks that were heretofore unavailable while simultaneously improving privacy, security, usability and accessibility of participant conditions, events and data.
    • 97. 发明授权
    • UTRs increasing the translation efficiency of RNA molecules
    • US11136585B2
    • 2021-10-05
    • US15739147
    • 2016-06-30
    • Ethris GmbH
    • Carsten RudolphManish Kumar AnejaMehrije FeriziJohannes Geiger
    • C07H21/04C12N15/67C07K14/47A61K38/00
    • Described is an RNA molecule comprising (a) a coding region coding for a polypeptide; and (b) upstream of said coding region one or more UTR(s) comprising the sequence as shown in SEQ ID NO:1 or a sequence which shows 1 to 4 substitutions in comparison to SEQ ID NO:1 and which results in an RNA molecule having the same or a higher translation efficiency as an RNA molecule comprising an UTR comprising SEQ ID NO:1; and/or (c) downstream of said coding region one or more UTR(s) comprising the sequence as shown in SEQ ID NO:2 or a sequence which shows 1 to 7 substitutions in comparison to SEQ ID NO:2 and which results in an RNA molecule having the same or a higher translation efficiency as an RNA molecule comprising an UTR comprising SEQ ID NO:2; wherein said polypeptide encoded by said coding region is not a cytochrome b-245 alpha polypeptide (CYBA). Moreover, described is a nucleic acid molecule encoding the RNA molecule according to the present invention. Further, described is a vector comprising the nucleic acid molecule according to the present invention and to a host cell comprising the vector according to the present invention. Further, described is a pharmaceutical composition comprising the RNA molecule according to the present invention and optionally a pharmaceutically acceptable carrier. Moreover, described is a kit comprising the RNA molecule according to the present invention. Finally, described is the use of one or more UTR(s) as defined in (b) and/or one or more UTR(s) as defined in (c) for increasing the efficiency of translating a coding region of an RNA molecule into a polypeptide or a protein encoded by said coding region.